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Impact of initial dialysis modality on
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Abstract
Background: Whether the choice of dialysis modality in patients with end stage renal disease may impact
mortality is undecided. No randomized controlled trial has properly addressed this issue. Propensity-matched
observational studies could give important insight into the independent effect of peritoneal (PD) opposed to
haemodialysis (HD) on all-cause and cardiovascular mortality.
Methods: To correct for case-mix differences between patients treated with PD and HD, propensity-matched
analyses were utilized in all patients who initiated dialysis as first renal replacement therapy in Norway in the period
2005–2012. PD patients were matched in a 1:1 fashion with HD patients, creating 692 pairs of patients with
comparable baseline variables. As-treated and intention-to treat analyses were undertaken to assess cardiovascular
and all-cause mortality. Interaction analyses were used to assess differences in the relationship between initial
dialysis modality and mortality, between strata of age, gender and prevalent diabetes mellitus.
Results: In the as-treated analyses, initial dialysis modality did not impact 2-year (PD vs. HD: HR 0.87, 95 % CI 0.67–1.12)
or 5-year all-cause mortality (HR 0.95, 95 % CI 0.77–1.17). In patients younger than 65 years, PD was superior
compared to HD with regard to both 2-year (HR 0.39, 95 % CI 0.19–0.81), and 5-year all-cause mortality (HR 0.49,
95 % CI 0.27–0.89). Cardiovascular mortality was also lower in the younger patients treated with PD (5-year HR 0.38,
95 % CI 0.15–0.96). PD was not associated with impaired prognosis in any of the prespecified subgroups compared
to HD. The results were similar in the as-treated and intention-to-treat analyses.
Conclusion: Survival in PD was not inferior to HD in any subgroup of patients even after five years of follow-up. In
patients below 65 years, PD yielded superior survival rates compared to HD. Increased use of PD as initial dialysis
modality in ESRD patients could be encouraged.
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Background
An aging population and increasing incidence of athero-
sclerotic disease, hypertension and diabetes have caused
a substantial rise in patients in need of renal replace-
ment therapy (RRT) in Norway similar to what has been
observed in other countries [1, 2]. Peritoneal dialysis
(PD) and haemodialysis (HD) are considered equivalent
treatment options in end stage renal disease (ESRD).
Preserved residual kidney function, reduced infection
risk and improved patient contentment, as well as
reduced cost and manpower use, are arguments for in-
creased use of PD [3]. Despite that, the proportion of pa-
tients treated with PD has remained stable in Norway
during the last two decades [1], but has decreased in
other countries [4].
Dialysis patients experience a high risk of all-cause
and cardiovascular mortality [5, 6]. Whether dialysis mo-
dality independently affects mortality is under debate.
No randomized controlled trial has been performed to
assess the independent effect of HD and PD on mortal-
ity, and this is unlikely to ever occur. Observational data
suggest that there is no difference in survival between
the two modalities [7–11]. Notwithstanding, a survival
advantage for PD the first years after dialysis initiation has
been reported in young patients without comorbidity, e.g.
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diabetes [12–15], while HD may be associated with im-
proved survival beyond 1–2 years in dialysis [16] . As the
need for RRT is increasing, particularly in developing
countries [2], and PD may provide RRT at lower cost and
higher patient contentment, there is a need to further clar-
ify whether initial dialysis modality may impact survival.
Observational studies that compare outcome differ-
ences between the two dialysis modalities may be limited
by confounding by indication. Patient treatment prefer-
ences, center experience, cause of ESRD, time of referral
to nephrologist, and comorbidity may all affect the
choice of initial dialysis modality. Thus, proper adjust-
ment for the case-mix differences between HD and PD
patients must be undertaken to solve the problem of this
bias. Propensity score matched analyses mimic some of
the characteristics of a randomized controlled trial and
may better correct for case-mix differences than trad-
itional regression analyses [17].
The aims of the current study were to utilize propen-
sity matched analyses to assess all-cause and cardiovas-
cular mortality in patients treated with PD compared to
HD as initial RRT. Furthermore, the aim was to investi-
gate if PD or HD were superior with respect to mortality
in any strata of age, gender and prevalent diabetes
mellitus.
Methods
Study population
The Norwegian Renal Registry is a national registry
comprising all ESRD patients residing in Norway who
receive RRT, both renal transplantation and chronic dia-
lysis. Patients are included in the registry when they first
start chronic dialysis treatment or receive a renal trans-
plant. Changes in RRT are recorded at the time of the
event, as is cessation of dialysis treatment, emigration
and death. Dialysis patients have been included in the
national registry from 1980. From 2005, patients starting
dialysis as first RRT were registered with more compre-
hensive data of baseline characteristics including labora-
tory values and comorbidity. Adult patients (>18 years)
who started dialysis as initial RRT in the time period
from January 2005 through December 2012 were in-
cluded in the current study. The study database con-
tained only 0.55 % missing data. No patient was lost to
follow-up.
All participants provided written informed consent be-
fore inclusion in the registry. Permission for the current
study was granted from the Regional Committee of
Medical and Health Research.
Definitions
Primary renal diagnosis was classified according to the
ERA-EDTA primary renal disease codes, and ERA-
EDTA cause of death (COD) codes were applied [18].
Cardiovascular cause of death was defined as a compos-
ite of COD group I–IV including myocardial ischemia
and infarction, heart failure, cardiac arrest/sudden death
and cerebrovascular accident [18].
Renal function at the time of dialysis initiation was
expressed as estimated glomerular filtration rate (eGFR)
using MDRD formula.
Previous heart disease was defined as a diagnosis of
coronary heart disease and/or heart failure prior to dia-
lysis initiation. Left ventricular hypertrophy (LVH)
should have been confirmed by echocardiography. Previ-
ous cerebrovascular disease (CVD) included previous
cerebrovascular insult or transischemic attack (TIA).
Peripheral arterial disease (PAD) was defined as estab-
lished atherosclerotic vascular disease other than vascu-
lar disease in the brain or heart, e.g. aortic aneurysm,
renovascular disease and intermittent claudication. Any
history of a malignant tumour diagnosis prior to dialysis
treatment was registered as previous malignancy.
Norway consists of 19 counties, both urban and rural
areas, some scarcely populated. Use of PD has varied
substantially between the counties through the years [1],
and this is most likely caused by the difference in experi-
ence and traditions in the renal units. Therefore, pa-
tients were propensity matched also according to county
affiliation.
Statistical analyses
Continuous variables were presented as mean ± SD, or
median and range if skewed. Categorical data were pre-
sented as percentage. Student t-tests were used to com-
pare normally distributed continuous variables between
patients in PD and HD. Mann-Whitney U-test was used
if data were skewed. Chi-square test was applied to com-
pare categorical data.
A time dependent logistic regression model was built
to create propensity scores of being treated with PD
compared to HD as the initial dialysis modality. As the
population started in PD may have changed in the study
period due to a challenged HD capacity in Norway, a in-
dividual propensity score of being treated with PD was
calculated separately in patients started in dialysis in the
period 2005 through 2008 and the period 2009 through
2012. Baseline covariates were entered as independent
variables in the model: age, gender, county, primary cause
of ESRD, comorbidities (diabetes mellitus, LVH, estab-
lished heart disease, PAD, CVD and previous malignancy),
eGFR, haemoglobin, serum albumin, number of antihy-
pertensive drugs, use of statins, erythropoietin stimulating
agents, vitamin D supplementation, candidate of future
transplantation and crashlanders (knowledge of the pa-
tients less than four months prior to start of dialysis). Less
than 1 % of the variables were missing. Patients with miss-
ing data were excluded from further analyses as a
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complete data set was mandatory to produce a propensity
score. PD patients were matched 1:1 with HD patients by
best match using R extension pack (R version 2.12.1) with
IBM SPSS Statistics [19].
Survival analyses were conducted both in the terms of
as-treated and intention-to-treat. In the as-treated ana-
lyses patients were censored for the earliest of the fol-
lowing: renal transplantation, dialysis modality change,
dialysis cessation, emigration or study end by December
2012. In the intention-to-treat analyses patients were
censored in the same way except that change in dialysis
modality did not induce end of follow-up time.
Kaplan-Meier plots and log-rank statistics were used to
analyse differences in survival between the initial dialysis
modalities in the propensity matched cohort. Hazard ra-
tios were calculated from univariate Cox regression ana-
lyses. The assumption of proportional hazard were
checked and found to be adequately met.
Stratified analyses were undertaken with respect to
age, gender and diabetes mellitus. Differences between
the strata were checked by interaction analyses by enter-
ing product terms into the Cox regression models.
Level of significance was set to 0.05. Analyses were
performed with IBM SPSS statistical software (version
20.0, IBM SPSS Statistics, New York, U.S.).
Results
A total of 3555 adult patients received dialysis as first ac-
tive ESRD treatment in Norway in the period from 2005
to 2012. A propensity score could be calculated in 3089
patients who had complete datasets (age 64.8 ±
15.3 years, 67 % men). HD was the most frequent initial
dialysis modality (n = 2407, 78 %), while 692 patients
(22 %) were started in PD. Median as-treated follow-up
time was 12 months (range 0–92). The baseline charac-
teristics of the included patients are presented in Table 1.
The unmatched case-mix differences between PD and
HD patients were substantial.
Patients with PD as initial modality were propensity
matched 1:1 with patients who started with HD. The
final analyses included 692 matched pairs of patients.
The differences in baseline characteristics between PD
and HD patients were balanced in the propensity match-
ing procedure (Table 1). The as-treated follow-up time
was lower in the PD group compared to the HD group
(median 10 (0–73) vs. 13 (0–89) months, p < 0.001). The
intention-to-treat follow-up time, i.e. patients were not
censored for change of dialysis modality, was equal in
the two groups (14 (0–95) months in PD vs. 15 (0–89)
months in HD, p = 0.359).
All-cause mortality was not affected by initial dialysis
modality in the as-treated analyses, (2-year PD vs. HD
HR 0.87, 95 % CI 0.67–1.12 and 5-year HR 0.95, 95 % CI
0.77–1.17, Fig. 1). Neither did dialysis modality impact
survival in the intention-to-treat analyses (Table 2).
In the stratified analyses, PD was associated with re-
duced all-cause mortality in patients aged below 65 years
(Fig. 2). The results were similar in both the as-treated
and intention-to-treat analyses (Table 2). PD was not as-
sociated with impaired survival in any subgroup of pa-
tients (Table 2).
Cardiovascular disease was the cause of death in 117
of 238 patients (49.1 %) at 2- year, and in 176 of 365 pa-
tients (48.2 %) at 5-year as-treated follow-up. In patients
younger than 65 years, 5-year as-treated cardiovascular
mortality was lower in PD compared to HD (HR 0.38,
95 % CI 0.15–0.96). This was not observed in patients
older than 65 years (p for interaction = 0.023). The
intention-to-treat analyses confirmed lower 5-year car-
diovascular mortality in the younger (HR 0.28 95 % CI
0.11–0.68).
No interactions between gender or diabetes mellitus
and initial dialysis modality were found concerning
mortality.
Discussion
Initial dialysis modality did not impact all-cause or car-
diovascular mortality in this propensity matched study.
However, the present study suggests that PD was more
favourable with respect to survival compared to HD in
patients below 65 years. Actually, 2-year all-cause mor-
tality was more than halved in the younger PD patients
compared to what was observed in HD patients, and the
improved all-cause and cardiovascular survival persisted
through five year of follow-up.
PD and HD have been considered to be equally effect-
ive as initial dialysis modalities concerning risk of mor-
tality [7–11]. Observational studies have also previously
reported favourable outcomes in younger PD patients
without comorbidities compared to HD patients, how-
ever limited to the first 1–2 years of dialysis treatment
[12–15]. The concern about increased mortality in PD
compared to HD if treatment is continued beyond 1–2
years is not supported by our study [16]. Furthermore,
elderly patients with diabetes mellitus have been claimed
to do worse in PD compared to HD [7, 11]. We did not
find any interaction between diabetes mellitus and dialy-
sis modality related to outcome. No investigated sub-
group had worse outcome in PD compared to HD in the
present study, whether using as-treated or intention-to-
treat analyses.
There are several reasons why our results may diverge
from that of previous studies comparing outcome in PD
and HD. Earlier studies are typically based on dialysis
registries with patients included in the late 1990s and
early 2000s [15, 16, 20]. Although survival for both HD
and PD patients has improved during the last decades,
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survival has improved more in PD patients than in HD
patients [21]. Our study included patients in the time
period 2005 to 2012. During this period, more physio-
logical dialysis solutions have been utilized for PD pa-
tients in Norway. Neutral-pH, low-glucose degradation
product PD solutions result in better preservation of re-
sidual renal function and greater urine output compared
to the traditional solutions [22]. Furthermore, the use of
icodextrin and amino acid as alternative to glucose as
osmotic agent may improve ultrafiltration capacity and
lessen the harmful effects caused by glucose [23]. Thus,
one may assume that our findings are partly explained
by the evolvement of PD treatment in the last decade,
suggesting that patients in the present study received
improved quality PD compared to patients in most pre-
vious studies.
Propensity matched analyses were used to correct for
the case-mix differences between patients treated with
HD and PD. Based on predefined measured variables,
patients starting PD were matched with HD patients
Table 1 Baseline characteristics of Norwegian patients starting peritoneal- or hemodialysis as initial renal replacement therapy in the
period 2005–2012
All Unmatched HD Matched HD PD p-values
(n = 3089) (n = 2407) (n = 682) (n = 682) PD vs. unmatched HD PD vs. matched HD
Age (years) 64.8 (15.3) 64.9 (15.4) 65.2 (15.0) 64.6 (15.2) NS NS
Male gender (%) 67.2 67.3 67.0 66.7 NS NS
County <0.001 NS
Renal diagnosis <0.001 NS
BMI kg/m2 25.9 (5.2) 26.1 (5.5) 25.5 (5.1) 25.4 (4.2) 0.001 NS
eGFR ml/min/1.73 m2 8.3 (3.2) 8.2 (3.2) 9.0 (3.4) 8.8 (3.1) <0.001 NS
Hb g/dl 10.6 (1.6) 10.4 (1.6) 11.2 (1.5) 11.3 (1.4) <0.001 NS
Albumin g/l 34.9 (6.7) 34.0 (6.7) 37.8 (5.5) 38.0 (5.7) <0.001 NS
Prev comorbidities
DM (%) 32.1 32.9 30.6 29.3 NS NS
Heart disease (%) 31.6 33.1 30.5 26.5 0.001 NS
LVH (%) 31.3 32.2 28.9 28.2 0.044 NS
CVD (%) 13.9 14.5 12.0 11.9 NS NS
PAD (%) 20.2 21.2 18.0 16.6 0.008 NS
Malignancy (%) 10.0 11.3 5.4 5.7 <0.001 NS
Medications
Number of BP medication (%) <0.001 NS
0 10.1 11.8 3.2 4.1
1 12.6 12.8 12.0 12.0
2 22.5 22.3 22.4 23.3
3 29.4 28.6 33.3 32.3
4 17.3 16.5 20.1 19.9
>4 8.1 8.1 8.9 8.4
Statin (%) 54.0 52.3 61.1 60.3 0.001 NS
Vitamin D (%) 59.1 55.6 70.4 71.4 <0.001 NS
ESA (%) 59.0 55.9 70.8 70.1 <0.001 NS
Known by nephrologist (%) 74.2 69.4 91.1 91.1 <0.001 NS
RTX candidate (%) 59.8 57.0 68.3 69.5 <0.001 NS
Follow-up time (months) 12 (0–92) 13.0 (0–89) 10.0 (0–73) <0.001
Continuous data are shown as mean ± SD, median (range) if skewed, and categorical data as percentages.
BMI: Body mass index, County: Patients were categorized due to situation in 19 counties in Norway, CVD: cerebrovascular disease, Diagnosis: patients were
categorized due primary renal diagnosis defined by ERA-EDTA primary renal disease codes, DM: diabetes mellitus, ESA: erythropoiesis stimulating agents, Follow-up
time: As-treated follow-up time prior to censoring or death, Heart disease: previous diagnosis of coronary heart disease or heart failure, Known by nephrologist:
treated by nephrologist > 4 months prior to dialysis initiation, LVH: left ventricular hypertrophy, Malignancy: previous diagnosis of malignant disease, PAD:
peripheral artery disease, RTX candidate: considered suitable for future renal transplantation by treating nephrologist, vitamin D: supplementation with active
vitamin D or paricalcitol
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with comparable baseline characteristics decided by pro-
pensity score. Propensity matched analyses open the
possibility to design and analyse observational data so
that it mimics some of the particular characteristics of a
randomized controlled trial and could be superior to
multivariate Cox regression to correct for confounding
factors in observational studies [17]. Randomized con-
trolled trials have been called for to assess the independ-
ent effect of dialysis modality on patient survival, but
will probably never be performed. Both Cox regression
and propensity matched analyses will be unable to prop-
erly correct for non-measured confounding variables.
Fig. 1 Kaplan-Meier 5-year survival plot comparing peritoneal- and haemodialysis as initial dialysis modality in 692 propensity matched pairs of patients
with end stage renal disease in Norway. As-treated, i.e. censored for change of dialysis modality, renal transplantation, dialysis cessation, emigration or
end of study (a) and intention-to-treat, i.e. censored for renal transplantation, dialysis cessation, emigration or end of study (b), analyses
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However, similar follow-up time in PD and HD patients
in the intention-to-treat analyses should indicate that
the propensity matched procedure was successful in cre-
ating comparable groups in our study.
Compared to similar studies that also used propensity
matched analyses, our patients were matched on a larger
number of variables and this should ensure improved re-
liability of our results [14, 24]. A recent American study
by Kumar et al. [14] used methods and definitions com-
parable to ours. In this study, the cumulative HR of
death favoured PD for up to three years in the as-treated
analyses with no difference therafter [14]. As our study
suggested favourable outcomes in PD in the younger pa-
tients, the difference in results from our study may be
explained by the age difference between the two popula-
tions. While the mean age of American PD patients was
57 years, the mean age in our population was 65 years in
PD as well as HD patients.
A higher rate of treatment failure is likely the cause of
the shorter as-treated follow-up time in PD patients com-
pared to that of HD patients. Technique failure is a major
challenge for the “PD-first” policy, and the failure rate has
not improved significantly the later years [3, 25]. PD was,
however, a safe initial dialysis modality in all subgroups of
patients in our study, as mortality rates were not affected
by a later need of treatment conversion in our intention-
to-treat analyses. High quality of care is important in PD,
and limited experience in the renal unit may limit the use
of PD as the initial treatment modality. According to our
Table 2 Cox regression all–cause mortality analyses comparing PD with HD as initial dialysis modality in 692 pairs of propensity
matched patients in Norway
a)
2-year all-cause mortality
As–treated Intention–to–treat
Hazard ratio 95 % CI p–value for interaction Hazard ratio 95 % CI p–value for interaction
All 0.87 0.67–1.12 0.93 0.73–1.18
Male 0.93 0.67–1.29 NS 1.03 0.77–1.38 NS
Female 0.77 0.50–1.17 0.79 0.53–1.16
DM- 0.75 0.55–1.02 NS 0.82 0.62–1.09 NS
DM+ 1.20 0.76–1.91 1.22 0.80–1.86
≤65 years 0.39 0.19–0.81 0.011 0.47 0.26–0.85 0.009
>65 years 1.03 0.78–1.36 1.11 0.86–1.44
b)
5-year all-cause mortality
As-treated Intention–to–treat
Hazard ratio 95 % CI p-value for interaction Hazard ratio 95 % CI p–value for interaction
All 0.95 0.77–1.17 0.99 0.82–1.19
Male 1.09 0.83–1.44 NS 1.06 0.83–1.34 NS
Female 0.78 0.55–1.09 0.87 0.65–1.19
DM- 0.91 0.70–1.18 NS 1.02 0.81–1.29 NS
DM+ 0.99 0.69–1.42 0.90 0.65–1.25
≤65 years 0.49 0.27–0.89 0.010 0.58 0.36–0.93 0.009
>65 years 1.06 0.84–1.33 1.13 0.92–1.39
Fig. 2 Kaplan-Meier 2-year survival plot comparing peritoneal- and
haemodialysis as initial dialysis modality in propensity matched patients
younger than 65 years
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findings, some patients may then be deprived of a superior
treatment.
In addition to the observational design of the study,
some limitations need to be mentioned. Analyses were re-
stricted to existing baseline variables in the Norwegian
Renal Registry at the time of dialysis initiation. Thus, we
were not able to match patients with regard to variables
not included in the registry. Time in dialysis is usually
short in Norway mainly due to high transplantation rates.
The median time of follow-up was shorter in our study
compared to what others have observed [9, 12, 15, 24].
Shorter median follow-up time could have affected our
statistical power to predict late complications of any dialy-
sis modality. Furthermore, the propensity matched ana-
lyses included only HD patients with similar baseline
characteristics as patients actually treated with PD in the
time period. As patients with baseline characteristics typ-
ically associated with HD are not included in our analyses,
generalization and applicability of our results to apply for
all ESRD patients should be done with care.
The choice of dialysis modality in individuals should
not be decided solely on mortality studies [26]. Patient
characteristics and preferences as well as, patient-related
outcomes and centre experience may impact the choice
[27, 28]. The use of PD has decreased in the western
world, leaving HD the prominent initial dialysis modality
in most countries [29, 30]. It is a paradox that less ex-
pensive equipotent treatment that may even provide im-
proved prognosis in selected patients is not more widely
preferred as initial ESRD treatment.
Conclusions
In this propensity matched study, PD as initial dialysis mo-
dality was not inferior to HD concerning five-year all-cause
or cardiovascular mortality in any investigated subgroup of
patients in the Norwegian dialysis population. PD as initial
dialysis modality conveyed favourable survival compared to
HD in patients younger than 65 years. Opposed to the
trend of exaggerated use of HD compared to PD, increased
use of PD could be advocated according to our data.
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